BNXT Share Price Performance
CA$0.91
0.65 (250.00%)
24.2% undervalued intrinsic discount
CA$1.20
Fair Value
Price CA$0.91
Ruhli CA$1.20
Fair ValueCA$1.20
Share PriceCA$0.91
24.2% undervalued intrinsic discount
BioNxt Solutions Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
BNXT Community Narratives
RU
Fair Value CA$1.2 28.3% undervalued intrinsic discount
New era of chemotherapy
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
Recent BNXT News & Updates
BioNxt Solutions Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.05
- Gross Margin
- 100.00%
- Net Profit Margin
- -27,871.54%
- Debt/Equity Ratio
- -84.0%
BioNxt Solutions Inc. Competitors
Snowflake Analysis
About BNXT
- Founded
- 2017
- Employees
- n/a
- CEO
- WebsiteView website
BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis; BNT23002 for the treatment of myasthenia gravis; BNT24002, a sublingual thin film for the treatment of lupus nephritis; BNT24003 for the treatment of rheumatoid arthritis; BNT24004 for longevity and anti-aging; and BNT24004 for the treatment of semaglutide. It also offers diagnostic screening tests; new active pharmaceutical production and evaluation, including precision transdermal and oral dissolvable drug formulations; infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
Canadian Market Performance
- 7 Days: 0.4%
- 3 Months: 10.0%
- 1 Year: 21.2%
- Year to Date: 19.9%
The market has been flat over the last week. As for the longer term, the market has risen 21% in the past 12 months. As for the next few years, earnings are expected to grow by 12% per annum. Market details ›